Vital KSK Holdings Incorporation operates in the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Vital KSK Holdings Incorporation with three other
drug stores in Asia:
China Medicine Health Industry Co Ltd
sales of 30.10 billion Chinese Renmimbi [US$4.77 billion]
Huadong Medicine Company Limited
(27.83 billion Chinese Renmimbi [US$4.41 billion]
of which 78%
was Commerce), and
China National Medicines Corp., Ltd.
based in China
(36.28 billion Chinese Renmimbi [US$5.74 billion]
of which 98%
was business department).
Vital KSK Holdings Incorporation reported sales of ¥581.08 billion (US$5.35 billion)
March of 2017.
decrease of 6.4%
versus 2016, when the company's sales were ¥621.04 billion.
The sales level in 2017 was fairly close to the level five years ago: in 2012, Vital KSK Holdings Incorporation had sales
of ¥541.65 billion.
Contributing to the drop in overall sales was the 6.7% decline
in Pharmaceuticals Sales, from ¥591.87 billion to ¥552.28 billion.
There were also decreases in sales in
Other (down 1.3% to ¥28.80 billion)